Literature DB >> 2012625

Serum keratan sulfate. Quantitative and qualitative comparisons in inflammatory versus noninflammatory arthritides.

F Mehraban1, C K Finegan, R W Moskowitz.   

Abstract

The concentration of keratan sulfate (KS) epitope was measured in the serum of patients with osteoarthritis (OA) or rheumatoid arthritis (RA) by enzyme-linked immunosorbent assay and compared with that in the serum of patients with primary fibromyalgia syndrome (PFS) and of controls who had no joint disease. By Student's tau-test, the mean serum KS concentrations in OA and RA patients measured with monoclonal antibodies (MAb) 5-D-4 and 2-D-3 were significantly increased over those in the PFS and normal groups; similar findings were observed using a nonparametric test, except that levels in RA patients showed no difference from those in PFS patients and normal subjects. There was no significant correlation between joint scores or disease duration and KS levels in OA or RA patients. Gel filtration of sera revealed mainly large, polydisperse KS-bearing fragments which eluted in a broad profile. KS purified from sera by immunoaffinity chromatography consisted mainly of high-density proteoglycans. Electrophoresis of pooled high-density KS fractions in polyacrylamide-agarose gels followed by Western blotting with MAb 5-D-4 showed diffuse bands with relative mobilities corresponding to large proteoglycans. These findings are consistent with attachment of KS to protein core fragments of various sizes; KS in patient sera is comparable in size with that in normal sera. Elevations of serum KS levels occur in the presence of cartilage degradation, but do not quantitatively define the extent or duration of articular involvement.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2012625     DOI: 10.1002/art.1780340403

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  The potential value of blood biomarkers of intervertebral disk metabolism in the follow-up of patients with sciatica.

Authors:  Federico Balagué; Margareta Nordin; Dominique Schafer; Ali Sheikhzadeh; Mary Ellen Lenz; Eugene M A Thonar
Journal:  Eur Spine J       Date:  2005-07-01       Impact factor: 3.134

2.  Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees.

Authors:  C Belcher; R Yaqub; F Fawthrop; M Bayliss; M Doherty
Journal:  Ann Rheum Dis       Date:  1997-05       Impact factor: 19.103

3.  Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now?

Authors:  A R Poole
Journal:  Ann Rheum Dis       Date:  1994-01       Impact factor: 19.103

Review 4.  Articular cartilage and osteoarthrosis. The role of molecular markers to monitor breakdown, repair and disease.

Authors:  L S Lohmander
Journal:  J Anat       Date:  1994-06       Impact factor: 2.610

5.  A sub-population of keratan sulphates derived from bovine articular cartilage is capped with alpha(2-6)-linked N-acetylneuraminic acid residues. Affinity chromatography using immobilized Sambucus nigra lectin and characterization using 1H n.m.r. spectroscopy.

Authors:  G H Tai; H G Morris; G M Brown; T N Huckerby; I A Nieduszynski
Journal:  Biochem J       Date:  1992-08-15       Impact factor: 3.857

6.  Assessment of glycosaminoglycan concentration in equine synovial fluid as a marker of joint disease.

Authors:  J L Palmer; A L Bertone; H McClain
Journal:  Can J Vet Res       Date:  1995-07       Impact factor: 1.310

7.  Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis.

Authors:  A R Poole; M Ionescu; A Swan; P A Dieppe
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

8.  Keratan sulphate in rheumatoid arthritis, osteoarthritis, and inflammatory diseases.

Authors:  T D Spector; L Woodward; G M Hall; A Hammond; A Williams; M G Butler; I T James; D J Hart; P W Thompson; D L Scott
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

9.  Hydroxytyrosol as a Promising Ally in the Treatment of Fibromyalgia.

Authors:  Jorge A Ramírez-Tejero; Esther Martínez-Lara; M Ángeles Peinado; María Luisa Del Moral; Eva Siles
Journal:  Nutrients       Date:  2020-08-09       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.